Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (750)	9/24/1998 8:09:00 PM
From: SDR-SI	Respond to of 1686

To all: Another successful defense of AVONEX by BGEN in the international market: > > >Biogen Announces that German Court Enjoins Schering A.G. From Issuing Inaccurate Information Relating to Avonex (Interferon Beta-1a) Dosing PR Newswire, Thursday, September 24, 1998 at 16:18 CAMBRIDGE, Mass., Sept. 24 /PRNewswire/ -- Biogen, Inc. (NASDAQ:BGEN) today announced that a District Court in Berlin has issued an injunction calling for Schering A.G. to stop making misleading statements relating to the dose of Biogen's AVONEX(R) (Interferon beta-1a), the world's leading treatment for relapsing forms of multiple sclerosis. The Company said that Schering has voluntarily consented to this cease and desist declaration and that violations would lead to both penalties against Schering and damages to Biogen. In its ruling, the German District Court said that Biogen has offered "prima facie evidence that its medication AVONEX(R) has been approved by the European Commission on the basis, amongst other things, of the dosage specified in the summary of the properties of this medication. This makes it likely to a large degree that the specified dosage is sufficient and is not an under-dosage." Jim Tobin, Biogen's Chief Executive Officer, said, "We are pleased that Schering has acknowledged that its statements about the dose of AVONEX(R) have been deliberately misleading. As a result of this decision, we expect Schering will behave more responsibly, not only in Germany, but throughout the entire global marketplace." AVONEX(R) is the world's most popular drug for treatment of relapsing forms of MS. It is the only drug proven to both slow the progression of relapsing MS and the number of disease exacerbations. In addition, it has a more convenient dosing regimen than its competitors and a moderate side-effect profile. Biogen, Inc., headquartered in Cambridge, MA, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The Company's revenues are generated from the worldwide sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon, hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen's Homepage on the World Wide Web at biogen.com. SOURCE Biogen, Inc. -0- 09/24/98 /CONTACT: Media: Kathryn R. Bloom, Director of Communications, 617-679-2851 or Investment Community: Elizabeth Woo, Manager, Investor Relations, 617-679-2812 both of Biogen, Inc./ < < < Steve

To: Harold Engstrom who wrote (750)	9/25/1998 2:25:00 PM
From: Hong-Lee Yu	Read Replies (1) \| Respond to of 1686

Harold, Let's hope so. Do you know how big secondary progressive market is ? To continue to grow at 25% or more beyond 1999 and before new drugs are on market in 2002, BGEN will need to make $3.75 -$4.00 per share by 2001. I think that they can achieve with 950M product sales (230M from royalty, 720M from Avonex).

To: Harold Engstrom who wrote (750)	9/27/1998 7:45:00 AM
From: Bwe	Read Replies (2) \| Respond to of 1686

Harold, BGEN just moved into a bearish p&f pattern called a High Pole Top (HPT) which I've written about on this thread before. The stock previously had a HPT at $55 in August and the stock eventually fell to $42 off that pattern. The main indicators that p&f chartist's follow are bullish now as opposed to being Bear Confirmed in August, and the aftereffects of the HPT, will, in all likelihood, be much less severe. However, HPT's are never a good chart pattern and the stock has had a great move rising 67% in less than a month. The stock has very bullish relative strength and has been outperforming the Dow since January of this year and gave a RS buy signal in March. The stock has previous buying support in the $59-60 range and trendline support at $62 and $55. I believe those levels represent a good opportunity to initiate or add to existing positions. For those who are tempted at this price level, I suggest showing patience for a better buying opportunity as the HPT suggests short term weakness. Take care, Bruce